Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;78(10):972-976.
doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.

Low-grade Serous Ovarian Carcinoma

Enzo Ricciardi  1 , Thaïs Baert  1   2 , Beyhan Ataseven  1 , Florian Heitz  1 , Sonia Prader  1 , Mareike Bommert  1 , Stephanie Schneider  1 , Andreas du Bois  1 , Philipp Harter  1
Affiliations

Low-grade Serous Ovarian Carcinoma

Enzo Ricciardi et al. Geburtshilfe Frauenheilkd. 2018 Oct.

Abstract
in English, German

In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

Kurz nach der Jahrtausendwende wurde ein 2-stufiges Klassifizierungssystem zur Einstufung von serösen Ovarialkarzinomen eingeführt. Seither wird zunehmend akzeptiert, dass das Low-grade seröse Ovarialkarzinom (LGSOC) eine eigenständige Einheit mit eigener Mutationslandschaft und klinischem Verhalten bildet. Weniger als 10% aller serösen Karzinome des Ovars werden dem Low-Grade-Subtyp zugeordnet, und in den klinischen Studien zum Ovarialkrebs tritt diese Form nur in wenigen Patientinnen auf. Die aktuelle Therapie für das LGSOC basiert daher auf den Ergebnissen kleinerer Studien und retrospektiver Serien sowie auf der Subgruppenanalyse von großen klinischen Studien zum Ovarialkarzinom. Die operative Therapie spielt eine wichtige Rolle für die Behandlung von Patientinnen mit LGSOC. Bei der systemischen Therapie des LGSOC scheinen sowohl hormonelle Therapien als auch gezielte Therapien eine wichtige Rolle zu spielen.

Keywords: low-grade serous; ovarian cancer; rare tumour.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors have no conflict of interest concerning this paper. General conflict of interest: TB: research funding: Amgen; conference travel expenses: Amgen, Roche; PH: advisory board: Astra Zeneca, Roche, Clovis, Tesaro, Pharmamar, Lily; honoraria: Astra Zeneca, Roche, Tesaro, Styker; AdB: advisory board: Pfizer, Astra Zeneca, Roche, Tesaro, Genmab, Pharmamar; honoraria: Astra Zeneca, Roche, MSD, Pharmamar; FH: advisory board: Tesaro, Roche; travel expenses: Boehringer Ingelheim, Astra Zeneca, Roche; BA: advisory board: Roche, Amgen, Tesaro; honorarium: Roche; travel expenses: Roche, Tesaro.

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. doi:10.1016/j.ejca.2012.12.027. Eur J Cancer. 2013;49:1374–1403. - PubMed
    1. Kurman R, Ellenson L H, Ronnett B M. Berlin, Heidelberg: Springer; 2011. Blausteinʼs Pathology of the female genital Tract. 6th ed.
    1. Malpica A, Deavers M T, Lu K. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504. - PubMed
    1. Kaldawy A, Segev Y, Lavie O. Low-grade serous ovarian cancer: A review. doi:10.1016/j.ygyno.2016.08.320. Gynecol Oncol. 2016;143:433–438. - PubMed
    1. Gershenson D M, Bodurka D C, Lu K H. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: Results of a large single-institution registry of a rare tumor. J Clin Oncol. 2015;33:2675–2682. - PMC - PubMed